PMID- 34546840
OWN - NLM
STAT- MEDLINE
DCOM- 20211228
LR  - 20220204
IS  - 2165-5987 (Electronic)
IS  - 2165-5979 (Print)
IS  - 2165-5979 (Linking)
VI  - 12
IP  - 1
DP  - 2021 Dec
TI  - Long intergenic non-protein coding RNA 02570 promotes nasopharyngeal carcinoma 
      progression by adsorbing microRNA miR-4649-3p thereby upregulating both sterol 
      regulatory element binding protein 1, and fatty acid synthase.
PG  - 7119-7130
LID - 10.1080/21655979.2021.1979317 [doi]
AB  - Our previous studies have elucidated a possible connection between long 
      intergenic non-protein coding RNA 2570 (LINC02570) and nasopharyngeal carcinoma 
      (NPC). However, the precise mechanism by which LINC02570 promotes NPC remains 
      unknown. We used quantitative polymerase chain reaction (qPCR) to detect 
      LINC02570 expression in nasopharyngeal cell lines, NPC tissues, and chronic 
      rhinitis tissues. Subcellular LINC02570 localization was confirmed by 
      fluorescence in situ hybridization (FISH). The effects of LINC02570 stable 
      knockdown and overexpression on viabillity, proliferation, migration, and 
      invasion were analyzed using 
      3-(4,5-Dimethyl-2-Thiazolyl)-2,5-Diphenyl-2-H-Tetrazolium bromide (MTT), a 
      colorimetric focus-formation assay, a wound healing assay, and transwell assays. 
      RNA crosstalk analysis in silico predicted microRNA-4649-3p (miR-4649-3p) binding 
      to LINC02570 or sterol regulatory element binding transcription factor 1 
      (SREBF1). A dual luciferase reporter assay was used to confirm potential 
      interactions. Sterol regulatory element binding protein 1 (SREBP1) and fatty acid 
      synthase (FASN) expression were detected by western blotting. The results suggest 
      that LINC02570 is upregulated in late clinical stage NPC patients, and promotes 
      NPC progression by adsorbing miR-4649-3p to up-regulate SREBP1 and FASN. This 
      study elucidates a potential chemotherapeutic target involved in lipid metabolism 
      in NPC.
FAU - Liu, Fei
AU  - Liu F
AD  - Research Center of Medical Sciences, The People's Hospital of Guangxi Zhuang 
      Autonomous Region, Guangxi Academy of Medical Sciences, Nanning City, P.R. China.
FAU - Wei, Jiazhang
AU  - Wei J
AD  - Department of Otolaryngology & Head and Neck, The People's Hospital of Guangxi 
      Zhuang Autonomous Region, Guangxi Academy of Medical Sciences, Nanning City, P.R. 
      China.
FAU - Hao, Yanrong
AU  - Hao Y
AD  - Cancer Center, The People's Hospital of Guangxi Zhuang Autonomous Region, Guangxi 
      Academy of Medical Sciences, Nanning City, P.R. China.
FAU - Lan, Jiao
AU  - Lan J
AD  - Research Center of Medical Sciences, The People's Hospital of Guangxi Zhuang 
      Autonomous Region, Guangxi Academy of Medical Sciences, Nanning City, P.R. China.
FAU - Li, Wei
AU  - Li W
AD  - Health Management Center, The People's Hospital of Guangxi Zhuang Autonomous 
      Region, Guangxi Academy of Medical Sciences, Nanning City, P.R. China.
FAU - Weng, Jingjin
AU  - Weng J
AD  - Department of Otolaryngology & Head and Neck, The People's Hospital of Guangxi 
      Zhuang Autonomous Region, Guangxi Academy of Medical Sciences, Nanning City, P.R. 
      China.
FAU - Li, Min
AU  - Li M
AD  - Department of Otolaryngology & Head and Neck, The People's Hospital of Guangxi 
      Zhuang Autonomous Region, Guangxi Academy of Medical Sciences, Nanning City, P.R. 
      China.
FAU - Su, Cheng
AU  - Su C
AD  - Research Center of Medical Sciences, The People's Hospital of Guangxi Zhuang 
      Autonomous Region, Guangxi Academy of Medical Sciences, Nanning City, P.R. China.
FAU - Li, Bing
AU  - Li B
AD  - Department of Otolaryngology & Head and Neck, The People's Hospital of Guangxi 
      Zhuang Autonomous Region, Guangxi Academy of Medical Sciences, Nanning City, P.R. 
      China.
FAU - Mo, Mingzheng
AU  - Mo M
AD  - Research Center of Medical Sciences, The People's Hospital of Guangxi Zhuang 
      Autonomous Region, Guangxi Academy of Medical Sciences, Nanning City, P.R. China.
FAU - Tang, Fengzhu
AU  - Tang F
AD  - Department of Otolaryngology & Head and Neck, The People's Hospital of Guangxi 
      Zhuang Autonomous Region, Guangxi Academy of Medical Sciences, Nanning City, P.R. 
      China.
FAU - Wang, Yongli
AU  - Wang Y
AD  - Department of Otolaryngology & Head and Neck, The People's Hospital of Guangxi 
      Zhuang Autonomous Region, Guangxi Academy of Medical Sciences, Nanning City, P.R. 
      China.
FAU - Yang, Yong
AU  - Yang Y
AD  - Department of Otolaryngology & Head and Neck, The People's Hospital of Guangxi 
      Zhuang Autonomous Region, Guangxi Academy of Medical Sciences, Nanning City, P.R. 
      China.
FAU - Jiao, Wei
AU  - Jiao W
AD  - Research Center of Medical Sciences, The People's Hospital of Guangxi Zhuang 
      Autonomous Region, Guangxi Academy of Medical Sciences, Nanning City, P.R. China.
FAU - Qu, Shenhong
AU  - Qu S
AD  - Department of Otolaryngology & Head and Neck, The People's Hospital of Guangxi 
      Zhuang Autonomous Region, Guangxi Academy of Medical Sciences, Nanning City, P.R. 
      China.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Bioengineered
JT  - Bioengineered
JID - 101581063
RN  - 0 (MicroRNAs)
RN  - 0 (RNA, Long Noncoding)
RN  - 0 (SREBF1 protein, human)
RN  - 0 (Sterol Regulatory Element Binding Protein 1)
RN  - EC 2.3.1.85 (FASN protein, human)
RN  - EC 2.3.1.85 (Fatty Acid Synthase, Type I)
SB  - IM
MH  - Cell Line, Tumor
MH  - Disease Progression
MH  - Fatty Acid Synthase, Type I/genetics/metabolism
MH  - Humans
MH  - MicroRNAs/*genetics/metabolism
MH  - *Nasopharyngeal Carcinoma/genetics/metabolism/mortality/pathology
MH  - *Nasopharyngeal Neoplasms/genetics/metabolism/mortality/pathology
MH  - Nasopharynx/pathology
MH  - RNA, Long Noncoding/*genetics/metabolism
MH  - Sterol Regulatory Element Binding Protein 1/genetics/metabolism
MH  - Up-Regulation
PMC - PMC8806647
OTO - NOTNLM
OT  - FASN
OT  - LINC02570
OT  - SREBP1
OT  - miR-4649-3p
OT  - nasopharyngeal carcinoma (NPC)
OT  - progression
COIS- The authors have no conflicts of interests to declare.
EDAT- 2021/09/22 06:00
MHDA- 2021/12/29 06:00
PMCR- 2021/09/21
CRDT- 2021/09/21 17:17
PHST- 2021/09/21 17:17 [entrez]
PHST- 2021/09/22 06:00 [pubmed]
PHST- 2021/12/29 06:00 [medline]
PHST- 2021/09/21 00:00 [pmc-release]
AID - 1979317 [pii]
AID - 10.1080/21655979.2021.1979317 [doi]
PST - ppublish
SO  - Bioengineered. 2021 Dec;12(1):7119-7130. doi: 10.1080/21655979.2021.1979317.